Vaccination of health care workers against pertussis: Meeting the need for safety within hospitals

Vaccine

Volumn 32, Issue 38, 2014, Pages 4840-4843

  Heininger, U ^a,b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Health care workers; Immunisation; Pertussis

Indexed keywords

ANTIBIOTIC AGENT; DIPHTHERIA TETANUS TOXOID; PERTUSSIS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL TRANSMISSION; BORDETELLA PERTUSSIS; HEALTH CARE PERSONNEL; HOSPITAL; HUMAN; IMMUNOGENICITY; OCCUPATIONAL SAFETY; PERTUSSIS; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VACCINATION; DISEASE OUTBREAKS; DISEASE TRANSMISSION; PREVENTION AND CONTROL; PREVENTIVE HEALTH SERVICE; WHOOPING COUGH;

DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DISEASE OUTBREAKS; HEALTH PERSONNEL; HUMANS; IMMUNIZATION PROGRAMS; INFECTIOUS DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; VACCINATION; WHOOPING COUGH;

EID: 84906057173     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.062     Document Type: Article

References (38)

1. Cherry J.D., Grimprel E., Guiso N., Heininger U., Mertsola J. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J 2005, 24:S25-S34.
2. Heininger U., Cherry J.D. Pertussis immunisation in adolescents and adults - Bordetella pertussis epidemiology should guide vaccination recommendations. Expert Opin Biol Ther 2006, 6:685-697.
3. Zepp F., Heininger U., Mertsola J., Bernatowska E., Guiso N., Roord J., et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011, 11:557-570.
4. Rothstein E., Edwards K. Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J 2005, 24:S44-S47.
5. Ward J.I., Cherry J.D., Chang S.J., Partridge S., Lee H., Treanor J., et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005, 353:1555-1563.
6. Lugauer S., Heininger U., Cherry J.D., Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002, 161:142-146.
7. Witt M.A., Katz P.H., Witt D.J. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012, 54:1730-1735.
8. Wymann M.N., Richard J.L., Vidondo B., Heininger U. Prospective pertussis surveillance in Switzerland, 1991-2006. Vaccine 2011, 29:2058-2065.
9. Alexander E.M., Travis S., Booms C., Kaiser A., Fry N.K., Harrison T.G., et al. Pertussis outbreak on a neonatal unit: identification of a healthcare worker as the likely source. J Hosp Infect 2008, 69:131-134.
10. Bassinet L., Matrat M., Njamkepo E., Aberrane S., Housset B., Guiso N. Nosocomial pertussis outbreak among adult patients and healthcare workers. Infect Control Hosp Epidemiol 2004, 25:995-997.
11. Boulay B.R., Murray C.J., Ptak J., Kirkland K.B., Montero J., Talbot E.A. An outbreak of pertussis in a hematology-oncology care unit: implications for adult vaccination policy. Infect Control Hosp Epidemiol 2006, 27:92-95.
12. Bryant K.A., Humbaugh K., Brothers K., Wright J., Pascual F.B., Moran J., et al. Measures to control an outbreak of pertussis in a neonatal intermediate care nursery after exposure to a healthcare worker. Infect Control Hosp Epidemiol 2006, 27:541-545.
13. Crameri S., Heininger U. Successful control of a pertussis outbreak in a university children's hospital. Int J Infect Dis 2008, 12:e85-e87.
14. Ward A., Caro J., Bassinet L., Housset B., O'Brien J.A., Guiso N. Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol 2005, 26:288-292.
15. Calugar A., Ortega-Sanchez I.R., Tiwari T., Oakes L., Jahre J.A., Murphy T.V. Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers. Clin Infect Dis 2006, 42:981-988.
16. Maltezou H.C., Wicker S., Borg M., Heininger U., Puro V., Theodoridou M., et al. Vaccination policies for health-care workers in acute health-care facilities in Europe. Vaccine 2011, 29:9557-9562.
17. Eberhardt K., Burckhardt M.A., Erb T., Heininger U. Implementation of pertussis immunization (dTap) for health-care workers in a University Children's Hospital in Switzerland. Abstract; 31st European Society for Paediatric Infectious Diseases (ESPID) Annual Meeting 2013.
18. Linnemann C.C., Ramundo N., Perlstein P.H., Minton S.D., Englender G.S., McCormick J.B., et al. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet 1975, 1:540-544.
19. Baugh V., McCarthy N. Outbreak of Bordetella pertussis among oncology nurse specialists. Occup Med (Lond) 2010, 60:401-405.
20. Beytout J., Launay O., Guiso N., Fiquet A., Baudin M., Richard P., et al. Safety of Tdap-IPV given 1 month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin 2009, 5:315-321.
21. Talbot E.A., Brown K.H., Kirkland K.B., Baughman A.L., Halperin S.A., Broder K.P. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010, 28:8001-8007.
22. Yih W.K., Nordin J.D., Kulldorff M., Lewis E., Lieu T.A., Shi P., et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 2009, 27:4257-4262.
23. Frampton J.E., Keating G.M. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization. BioDrugs 2006, 6:371-389.
24. Scott L.J. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults. Bio Drugs 2010, 24:387-406.
25. Baxter R., Bartlett J., Rowhani-Rahbar A., Fireman B., Klein N.P. Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ 2013, 347:f4249. 10.1136/bmj.f4249.
26. Rank C., Quinn H.E., McIntyre P.B. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J 2009, 28:152-153.
27. Wei S.C., Tatti K., Cushing K., Rosen J., Brown K., Cassiday P., et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010, 51:315-321.
28. Hoppe J.E. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group. Pediatr Infect Dis J 1992, 11:189-193.
29. Goins W.P., Edwards K.M., Vnencak-Jones C.L., Rock M.T., Swift M., Thayer V., et al. A comparison of 2 strategies to prevent infection following pertussis exposure in vaccinated healthcare personnel. Clin Infect Dis 2012, 54:938-945.
30. Bundesamt für Gesundheit. Massnahmen zur Verhinderung und Bekämpfung von Pertussis-Ausbrüchen in Gesundheits- und Kinderbetreuungseinrichtungen zum Schutz von Säuglingen jünger als 6 Monate. BAG Bulletin 13/2011 [accessed 27.05.13]. http://www.bag.admin.ch/dokumentation/publikationen/01435/13591/index.html%3Flang=de.
31. Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (CDC) Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011, 60(RR-7):1-45.
32. Health Protection Agency Public Health Management of Pertussis. HPA Guidelines for the Public Health Management of Pertussis Incidents in Healthcare Settings 2012, http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136713302 [accessed 27.05.13].
33. Kirkland K.B., Talbot E.A., Decker M.D., Edwards K.M. Kinetics of pertussis immune responses to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for outbreak control. Clin Infect Dis 2009, 49:584-587.
34. The German Standing Committee on Vaccination Recommendations (STIKO) 2013, http://www.rki.de/EN/Content/Prevention/Vaccination/Vaccination_node.html [accessed 27.05.13].
35. Babcock H.M., Gemeinhart N., Jones M., Dunagan W.C., Woeltje K.F. Mandatory influenza vaccination of health care workers: translating policy to practice. Clin Infect Dis 2010, 50:459-464.
36. Centers for Disease Control and Prevention Updated Tdap Vaccination Coverage Rates. 2009 Adult vaccination coverage, National Interview Survey 2013, Available at http://www.cdc.gov/vaccines/stats-surv/nhis/downloads/tdap-tables-mmwr-NHIS-2009.xlsx [accessed 27.05.13].
37. Bailleux F., Coudeville L., Kolenc-Saban A., Bevilacqua J., Barreto L., André P. Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 2008, 26:3903-3908.
38. Mertsola J., Van Der Meeren O., He Q., Linko-Parvinen A., Ramakrishnan G., Mannermaa L., et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010, 51:656-662.